Shopping Cart
- Remove All
- Your shopping cart is currently empty
NYX-2925, an orally active NMDAR (N-methyl-D-aspartate receptor) modulator, enhances activated Src levels and Src phosphorylation at GluN2A and GluN2B sites in the mPFC (medial prefrontal cortex), without affecting CAMKII (Ca2+/calmodulin-dependent protein kinase II) or exhibiting addictive or sedative/ataxic side effects. It is utilized in the study of various CNS (central nervous system) disorders mediated by NMDA receptors.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $2,270 | 10-14 weeks | |
50 mg | $2,980 | 10-14 weeks | |
100 mg | $4,000 | 10-14 weeks |
Description | NYX-2925, an orally active NMDAR (N-methyl-D-aspartate receptor) modulator, enhances activated Src levels and Src phosphorylation at GluN2A and GluN2B sites in the mPFC (medial prefrontal cortex), without affecting CAMKII (Ca2+/calmodulin-dependent protein kinase II) or exhibiting addictive or sedative/ataxic side effects. It is utilized in the study of various CNS (central nervous system) disorders mediated by NMDA receptors. |
Molecular Weight | 297.35 |
Formula | C14H23N3O4 |
Cas No. | 2012536-16-0 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.